The presence of p53 mutants in the nuclei of cancer cells results in gain-of-function effects. These effects lead to poor prognosis in cancer patients with p53 mutations. This study aimed to synthesize 3-(4-chlorophenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one. The synthesis was carried out using the Knoevenagel condensation method. We reacted 0.025 mmol of 4-chlorobenzaldehyde with 0.025 mmol of ethyl acetoacetate in the presence of 0.025 mmol of diethylamine as a catalyst. The mixture was stirred for 1 hour at room temperature. The synthesized compound was recrystallized using a hot distilled water and ethanol mixture (3:2). This process yielded a yellowish-white crystal with a yield of 26% and a melting point range of 149.5–150.9°C. Structural elucidation using infrared spectrophotometry, mass spectrometry, and ¹H and ¹³C nuclear magnetic resonance confirmed that the synthesized compound was 3-(4-chlorophenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one.